2026 Q2 - tulosraportti
42 päivää sitten
‧32 min
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 1 000 | - | - | ||
| 259 | - | - | ||
| 3 400 | - | - | ||
| 3 240 | - | - | ||
| 400 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 - tulosraportti 19.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 20.8. | ||
2026 Q1 - tulosraportti 21.5. | ||
2025 Q4 - tulosraportti 26.3. | ||
2025 Q3 - tulosraportti 19.11.2025 | ||
2025 Q2 - tulosraportti 15.8.2025 |
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·9 t sittenBioPorto meets investors Thursday, October 8, 2026 Forskerparken in Odense in collaboration with Forskerparken, Økonomisk Ugebrev and Life Science Fyn. Registration for DAF Fyn - few seats available (only for DAF members) Wednesday, October 7, 2026 BioPorto in Hellerup "Unlocking the Growth" Registration for BioPorto That bodes well!
Can you make it? Unfortunately I cannot. I asked them last year if they will stream this online from Hellerup, because it can be done, but they didn't, and neither did anyone come with a presentation about what was said. unfortunately. Will / can you attend?- ·12 t sittenGrand View Research is one of the largest analysis firms. This analysis states that the market for AKI diagnostics (equipment for detecting acute kidney injury) will grow massively towards 2030 and become worth billions of dollars. Overview of the market for acute kidney injury (AKI) diagnostics The global acute kidney injury (AKI) diagnostics market was valued at 970.6 million USD in 2025 and is expected to grow from 1,033.6 million USD in 2026 to 1,709.6 million USD in 2033, with a compound annual growth rate (CAGR) of 7.5% from 2026 to 2033. North America dominated the market, accounting for the largest revenue share of 38.6% in 2025. Market growth is primarily driven by the increasing incidence of AKI among critically ill and hospitalized patients, combined with the rising adoption of rapid biomarker-based diagnostic tests for earlier detection and timely clinical intervention. https://www.grandviewresearch.com/industry-analysis/acute-kidney-injury-diagnostic-market-report
Grand View Research is one of the largest analysis houses? I have never heard of that major analysis before..... Anyone? - ·2 päivää sittenBioPorto: Clinical experts in focus at investor event by Michael Friis https://www.inderes.dk/analyst-comments/bioporto-kliniske-eksperter-i-fokus-pa-investorevent?utm_source=nordnet&utm_medium=integration
·2 päivää sittenThe Danish stock market is unfortunately characterized by negative investors who help influence share prices in a negative direction. When you spend money on investing in stocks, you need to have ice in your stomach and if you don't have that, you should not invest in stocks. I am not affected by these posts and have not sold out of my 30,000 pieces and neither have others like GN.- ·2 päivää sitten · MuokattuI have just discovered that from September 16th to 19th there has been a congress in Brazil in Belo Horizonte, Brazil, September 2026 On September 17th, KDIGO held their major, central AKI session (acute kidney injuries) at the congress. One of the keynote speakers was Marlies Ostermann. (Marlies Ostermann is co-chair and senior professional leader of the working group at KDIGO regarding the NGAL test) She came to speak about KDIGO's guidelines for the NGAL test. Marlies Ostermann explained the major paradigm shift that the working group is rolling out. She emphasized that clinics must no longer wait for serum creatinine to rise before they act (this method takes 48 hours to find out if there is a problem with the kidneys) Here she highlighted the importance of structural biomarkers, such as NGAL, to identify cell damage in the kidneys at a very early stage – long before the kidney's filtration capacity (function) drops. https://kdigo.org/events/kdigo-sessions-cbn-2026/Although KDIGO has not published the clean documents yet (to my knowledge), but they have reached so far in the working group, the persons who have been part of this working group, are seriously going out to recognized fairs and congresses to spread KDIGO's recommendations about the NGAL test. They do this by emphasizing that the former method "serum-creatinine" must not be used anymore. Now Bioporto has unusually busy days, because it is not only themselves who are going out to their future customers, to inform about KDIGO's recommendations. Now the persons who have been in KDIGO's working group are going out publicly and saying that the old method is forbidden to use and that they must use the NGAL test going forward. Now the question is whether KDIGO has avoided that there will be bottlenecks with the delivery and implementation of the NGAL test, which they wanted to avoid by publishing a draft with their recommendations in March 2026. My best guess, that they have not avoided it, because then Bioporto should have had more orders in H1 than they got.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tuotteita joiden kohde-etuutena tämä arvopaperi
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 266 163 | 266 163 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 266 163 | 266 163 | 0 | 0 |
2026 Q2 - tulosraportti
42 päivää sitten
‧32 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·9 t sittenBioPorto meets investors Thursday, October 8, 2026 Forskerparken in Odense in collaboration with Forskerparken, Økonomisk Ugebrev and Life Science Fyn. Registration for DAF Fyn - few seats available (only for DAF members) Wednesday, October 7, 2026 BioPorto in Hellerup "Unlocking the Growth" Registration for BioPorto That bodes well!Can you make it? Unfortunately I cannot. I asked them last year if they will stream this online from Hellerup, because it can be done, but they didn't, and neither did anyone come with a presentation about what was said. unfortunately. Will / can you attend?
- ·12 t sittenGrand View Research is one of the largest analysis firms. This analysis states that the market for AKI diagnostics (equipment for detecting acute kidney injury) will grow massively towards 2030 and become worth billions of dollars. Overview of the market for acute kidney injury (AKI) diagnostics The global acute kidney injury (AKI) diagnostics market was valued at 970.6 million USD in 2025 and is expected to grow from 1,033.6 million USD in 2026 to 1,709.6 million USD in 2033, with a compound annual growth rate (CAGR) of 7.5% from 2026 to 2033. North America dominated the market, accounting for the largest revenue share of 38.6% in 2025. Market growth is primarily driven by the increasing incidence of AKI among critically ill and hospitalized patients, combined with the rising adoption of rapid biomarker-based diagnostic tests for earlier detection and timely clinical intervention. https://www.grandviewresearch.com/industry-analysis/acute-kidney-injury-diagnostic-market-reportGrand View Research is one of the largest analysis houses? I have never heard of that major analysis before..... Anyone?
- ·2 päivää sittenBioPorto: Clinical experts in focus at investor event by Michael Friis https://www.inderes.dk/analyst-comments/bioporto-kliniske-eksperter-i-fokus-pa-investorevent?utm_source=nordnet&utm_medium=integration
- ·2 päivää sittenThe Danish stock market is unfortunately characterized by negative investors who help influence share prices in a negative direction. When you spend money on investing in stocks, you need to have ice in your stomach and if you don't have that, you should not invest in stocks. I am not affected by these posts and have not sold out of my 30,000 pieces and neither have others like GN.
- ·2 päivää sitten · MuokattuI have just discovered that from September 16th to 19th there has been a congress in Brazil in Belo Horizonte, Brazil, September 2026 On September 17th, KDIGO held their major, central AKI session (acute kidney injuries) at the congress. One of the keynote speakers was Marlies Ostermann. (Marlies Ostermann is co-chair and senior professional leader of the working group at KDIGO regarding the NGAL test) She came to speak about KDIGO's guidelines for the NGAL test. Marlies Ostermann explained the major paradigm shift that the working group is rolling out. She emphasized that clinics must no longer wait for serum creatinine to rise before they act (this method takes 48 hours to find out if there is a problem with the kidneys) Here she highlighted the importance of structural biomarkers, such as NGAL, to identify cell damage in the kidneys at a very early stage – long before the kidney's filtration capacity (function) drops. https://kdigo.org/events/kdigo-sessions-cbn-2026/Although KDIGO has not published the clean documents yet (to my knowledge), but they have reached so far in the working group, the persons who have been part of this working group, are seriously going out to recognized fairs and congresses to spread KDIGO's recommendations about the NGAL test. They do this by emphasizing that the former method "serum-creatinine" must not be used anymore. Now Bioporto has unusually busy days, because it is not only themselves who are going out to their future customers, to inform about KDIGO's recommendations. Now the persons who have been in KDIGO's working group are going out publicly and saying that the old method is forbidden to use and that they must use the NGAL test going forward. Now the question is whether KDIGO has avoided that there will be bottlenecks with the delivery and implementation of the NGAL test, which they wanted to avoid by publishing a draft with their recommendations in March 2026. My best guess, that they have not avoided it, because then Bioporto should have had more orders in H1 than they got.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 1 000 | - | - | ||
| 259 | - | - | ||
| 3 400 | - | - | ||
| 3 240 | - | - | ||
| 400 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 - tulosraportti 19.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 20.8. | ||
2026 Q1 - tulosraportti 21.5. | ||
2025 Q4 - tulosraportti 26.3. | ||
2025 Q3 - tulosraportti 19.11.2025 | ||
2025 Q2 - tulosraportti 15.8.2025 |
Tuotteita joiden kohde-etuutena tämä arvopaperi
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 266 163 | 266 163 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 266 163 | 266 163 | 0 | 0 |
2026 Q2 - tulosraportti
42 päivää sitten
‧32 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 - tulosraportti 19.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 20.8. | ||
2026 Q1 - tulosraportti 21.5. | ||
2025 Q4 - tulosraportti 26.3. | ||
2025 Q3 - tulosraportti 19.11.2025 | ||
2025 Q2 - tulosraportti 15.8.2025 |
Tuotteita joiden kohde-etuutena tämä arvopaperi
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·9 t sittenBioPorto meets investors Thursday, October 8, 2026 Forskerparken in Odense in collaboration with Forskerparken, Økonomisk Ugebrev and Life Science Fyn. Registration for DAF Fyn - few seats available (only for DAF members) Wednesday, October 7, 2026 BioPorto in Hellerup "Unlocking the Growth" Registration for BioPorto That bodes well!Can you make it? Unfortunately I cannot. I asked them last year if they will stream this online from Hellerup, because it can be done, but they didn't, and neither did anyone come with a presentation about what was said. unfortunately. Will / can you attend?
- ·12 t sittenGrand View Research is one of the largest analysis firms. This analysis states that the market for AKI diagnostics (equipment for detecting acute kidney injury) will grow massively towards 2030 and become worth billions of dollars. Overview of the market for acute kidney injury (AKI) diagnostics The global acute kidney injury (AKI) diagnostics market was valued at 970.6 million USD in 2025 and is expected to grow from 1,033.6 million USD in 2026 to 1,709.6 million USD in 2033, with a compound annual growth rate (CAGR) of 7.5% from 2026 to 2033. North America dominated the market, accounting for the largest revenue share of 38.6% in 2025. Market growth is primarily driven by the increasing incidence of AKI among critically ill and hospitalized patients, combined with the rising adoption of rapid biomarker-based diagnostic tests for earlier detection and timely clinical intervention. https://www.grandviewresearch.com/industry-analysis/acute-kidney-injury-diagnostic-market-reportGrand View Research is one of the largest analysis houses? I have never heard of that major analysis before..... Anyone?
- ·2 päivää sittenBioPorto: Clinical experts in focus at investor event by Michael Friis https://www.inderes.dk/analyst-comments/bioporto-kliniske-eksperter-i-fokus-pa-investorevent?utm_source=nordnet&utm_medium=integration
- ·2 päivää sittenThe Danish stock market is unfortunately characterized by negative investors who help influence share prices in a negative direction. When you spend money on investing in stocks, you need to have ice in your stomach and if you don't have that, you should not invest in stocks. I am not affected by these posts and have not sold out of my 30,000 pieces and neither have others like GN.
- ·2 päivää sitten · MuokattuI have just discovered that from September 16th to 19th there has been a congress in Brazil in Belo Horizonte, Brazil, September 2026 On September 17th, KDIGO held their major, central AKI session (acute kidney injuries) at the congress. One of the keynote speakers was Marlies Ostermann. (Marlies Ostermann is co-chair and senior professional leader of the working group at KDIGO regarding the NGAL test) She came to speak about KDIGO's guidelines for the NGAL test. Marlies Ostermann explained the major paradigm shift that the working group is rolling out. She emphasized that clinics must no longer wait for serum creatinine to rise before they act (this method takes 48 hours to find out if there is a problem with the kidneys) Here she highlighted the importance of structural biomarkers, such as NGAL, to identify cell damage in the kidneys at a very early stage – long before the kidney's filtration capacity (function) drops. https://kdigo.org/events/kdigo-sessions-cbn-2026/Although KDIGO has not published the clean documents yet (to my knowledge), but they have reached so far in the working group, the persons who have been part of this working group, are seriously going out to recognized fairs and congresses to spread KDIGO's recommendations about the NGAL test. They do this by emphasizing that the former method "serum-creatinine" must not be used anymore. Now Bioporto has unusually busy days, because it is not only themselves who are going out to their future customers, to inform about KDIGO's recommendations. Now the persons who have been in KDIGO's working group are going out publicly and saying that the old method is forbidden to use and that they must use the NGAL test going forward. Now the question is whether KDIGO has avoided that there will be bottlenecks with the delivery and implementation of the NGAL test, which they wanted to avoid by publishing a draft with their recommendations in March 2026. My best guess, that they have not avoided it, because then Bioporto should have had more orders in H1 than they got.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 1 000 | - | - | ||
| 259 | - | - | ||
| 3 400 | - | - | ||
| 3 240 | - | - | ||
| 400 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 266 163 | 266 163 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 266 163 | 266 163 | 0 | 0 |